Screener
ANI Pharmaceuticals ANIP Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts receivable, net | 274,469 | 281,082 |
| Inventories | 143,149 | 143,067 |
| Prepaid expenses and other current assets | 31,942 | 34,216 |
| Investment in equity securities | 15,626 | 9,131 |
| Total Current Assets | 825,433 | 753,117 |
| Non-current Assets | ||
| Property and equipment, net | 73,223 | 62,476 |
| Deferred tax assets, net | 71,495 | 69,072 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's cumulative cost basis?
- ANI Pharmaceuticals (ANIP) reported cumulative cost basis of $15.63M in Q2 2026.
- How has ANI Pharmaceuticals's cumulative cost basis changed year-over-year?
- ANI Pharmaceuticals's cumulative cost basis increased by 173.3% year-over-year, from $5.72M to $15.63M.
- What is the long-term trend for ANI Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's cumulative cost basis has grown at a -31.1% compound annual growth rate (CAGR), from $58.8M to $9.13M.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about ANI Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude